Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Consultants To Pre-Inspect Zovant Contract Manufacturing Sites

Executive Summary

Lilly's outside consultants will perform mock inspections of the contracted manufacturing sites producing Zovant, VP-Manufacturing Scott Canute said during a first quarter earnings call April 16.

You may also be interested in...



Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic

Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines

Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic

Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines

Lilly Xigris Action Date Is Oct. 27; FDA Preparing For Advisory Cmte. Review

The FDA user fee action date for Lilly's sepsis therapy Xigris (formerly Zovant) is extended until Oct. 27.

Related Content

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel